{"ticker": {"uuid": "2f22aea0-5a20-444f-9171-1cea7579275f", "symbol": "CRIS", "name": "Curis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Curis stock jumps 11% on positive emavusertib trial data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQb0dkTmJfWU03cUhlN0ZnWk9iVjl5RVB0TGtacTk1NzZzdE5NUnMwQ05WajgwRFRqNVByR1ZueXA4MERxbkFUQzNXWm9wREZlZ2xTSTF1UXo0UUZvTHFhcHFlcWFQRmtnTkFkZVN5a1N6TjVnVndSbkliaVI3NlQ3X0czdGNFY1o4ZDUwMGxVcUhSTkNwYnBibGhicm5sQ0ktRDdVQklYbTZjdjJBY2w4Zk5EZ2JUQk0?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-22T12:03:48+00:00", "published_display": "22 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces Positive Emavusertib Update", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/curis-announces-positive-emavusertib-110000703.html", "source_name": "PR Newswire", "published_at": "2026-07-22T11:00:00+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis has consented 10 CLL patients; first five expected to dose by July's end", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNV0Jmbk5HLVlMTmM3TlNPZHVmVG1XSU1UX2JjWDNITTd0ZXd0RmZjY1hzaWxDNmNCNW80UGEyOG5vUnI5c29OU0xZZ1RmM3hGbmU2Y1pOYkltLWd4bFhuZVotMkZSUEdhWktqRHdxUlFWRDVYOURuYS1BT091Xy1qY3ZNeVVFc3Y3Z0NNLU0zbHp2WXU5Umc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T11:00:00+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Equity in earnings of Curis, Inc. \u2013 SWB:CUS1", "summary": "The article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its equity in earnings, with data sourced from ICE Data Services and FactSet. It indicates that the market for this stock is currently closed, with no trades reported.", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-07-16T05:40:18", "published_display": "16 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of Curis, Inc. \u2013 SWB:CUS1", "summary": "This article focuses on the long-term debt to total equity ratio of Curis, Inc. (SWB:CUS1) as presented on TradingView. It appears to be a financial data page rather than a traditional article, providing a snapshot of this key financial metric for the biotechnology company. The c", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-07-15T04:12:10", "published_display": "15 Jul 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 SWB:CUS1", "summary": "This article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its price-to-book forward ratio. It's listed on the Stuttgart Stock Exchange under Health Technology/Biotechnology. The page displays general financial data, with market data provided", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:16:58", "published_display": "14 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (DB:CUS1) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Curis (DB:CUS1), a biotechnology company specializing in cancer drug development. It covers the company's valuation, future growth prospects, past performance, financial health, and dividend policy, along with recent news and upd", "url": "https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-cus1/curis-shares", "source_name": "Simply Wall Street", "published_at": "2026-07-14T03:16:58", "published_display": "14 Jul 2026 03:16", "sentiment": "negative", "sentiment_pct": 20, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curis, Inc. (CUS1) Company Information", "summary": "This article provides company information for Curis, Inc. (CUS1), detailing its exchange listings, key information such as its ticker, industry, sector, and market capitalization, and sources of financial data. It also lists the number of employees, location, and the analysts who", "url": "https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-cus1/curis-shares/information", "source_name": "Simply Wall Street", "published_at": "2026-07-12T05:10:43", "published_display": "12 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net margin % of Curis, Inc. \u2013 DUS:CUS1", "summary": "This article provides the net margin percentage for Curis, Inc. (DUS:CUS1) on the TradingView platform. It shows the value and change over a period, indicating financial performance. The data is part of a larger financial overview for the company available on the platform.", "url": "https://www.tradingview.com/symbols/DUS-CUS1/financials-statistics-and-ratios/net-margin/", "source_name": "TradingView", "published_at": "2026-07-10T16:40:44", "published_display": "10 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) director John Hohneker receives 6,800 stock options at $5.29", "summary": "Curis Inc. director John Hohneker was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options, which relate to 6,800 shares of common stock, will vest entirely on July 7, 2027, and have an expiration date of July 6, 2036. This transactio", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-fcba261a8d1f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T01:40:44", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) CDO Jonathan Zung receives 48,285 stock options at $5.29 strike", "summary": "Jonathan B. Zung, Chief Development Officer of Curis Inc. (CRIS), was granted 48,285 employee stock options with an exercise price of $5.29 per share. These options are part of his compensation, designed to vest over time with 25% vesting on July 7, 2027, and subsequent quarterly", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-a90a83ce556c.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURIS (CRIS) CFO receives 48,285 stock options at $5.29 exercise price", "summary": "CURIS (CRIS) CFO Diantha Duvall was granted 48,285 employee stock options with an exercise price of $5.29 per share as part of her compensation. The options will vest over time, with 25% vesting on July 7, 2027, and subsequent quarterly vesting until July 7, 2030, and will expire", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-54909ecc2dc0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURIS INC (CRIS) director granted 6,800 non-qualified stock options at $5.29", "summary": "CURIS INC director Anne Elizabeth Borgman was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This grant represents compensation-related equity rather t", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-2bd7149b0c57.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) director receives grant of 6,800 non-qualified stock options", "summary": "Curis Inc. director Kenneth I. Kaitin received a grant of 6,800 non-qualified stock options, exercisable at $5.29 per share. These options, which vest fully on July 7, 2027, and expire on July 6, 2036, are a compensation-related equity award rather than an open-market transaction", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-1b59c66ec14f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 HAM:CUS1", "summary": "This article provides financial information for Curis, Inc. (HAM:CUS1), specifically focusing on its \"Price to book forward\" metric. The content appears to be a financial data snippet from TradingView, indicating that the market for HAM:CUS1 is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/HAM-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Marc Rubin receives 6,800 Curis (CRIS) stock options at $5.29", "summary": "Curis Inc. director Marc Rubin was granted 6,800 non-qualified stock options at an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This transaction is considered a compensation-related award rather than", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-04073b6b912e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Curis Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Curis Inc. (CRIS) dated July 9th. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by officers, directors, and 10% shareholders. The specific details of the Form 4 are not provided beyond the", "url": "https://ca.investing.com/news/stock-market-news/form-4-curis-inc-for-9-july-93CH-4728027", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (CRIS) director receives 6,800 stock options at $5.29", "summary": "Curis Inc. director Martyn D. Greenacre was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options expire on July 6, 2036, and will vest completely on July 7, 2027. This transaction, categorized as an \"A\" grant, links the director's com", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-4b8008a2eed2.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) CEO receives 110,090 employee stock options at $5.29", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTWNlcEtqWHJDSUo1dC1XLWJTSDNyaXVZM2Z6UTMzeV81MVMybGFra2hidUp1aDRuZ3hSNUxPT3lyR08wNkJwUG0tVjJDaTlwZFBOM054UWJBdlJsR2RDR1pYaFo4NGZKUFRZYThSek1VaUpYanJ6WXdTUTJwaHNXMTd0bEt4VjVHT0lsWFVvMmQwNzNvUTNhYXZWemlUYkNnSkd6VERB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Curis, Inc. \u2013 LSX:A42DTL", "summary": "This article provides financial information for Curis, Inc. (LSX:A42DTL), specifically focusing on its free cash flow per share. It is presented on TradingView, a platform offering market data and financial tools.", "url": "https://www.tradingview.com/symbols/LSX-A42DTL/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-08T23:12:25", "published_display": "08 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 FWB:CUS1", "summary": "The article \"Price to book forward of Curis, Inc. \u2013 FWB:CUS1\" appears to be a stub or a placeholder page from TradingView, specifically concerning the financial metrics of Curis, Inc. (CUS1) on the Frankfurt Stock Exchange. It indicates that there is currently no trade data avail", "url": "https://www.tradingview.com/symbols/FWB-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T18:12:25", "published_display": "08 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 MUN:CUS1", "summary": "This article provides financial information for Curis, Inc. (MUN:CUS1) on the Munich Stock Exchange, specifically focusing on its price-to-book forward ratio. It indicates that the market is closed with no recent trades. The content is primarily a data placeholder within a larger", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:40:14", "published_display": "08 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Basic earnings per share (basic EPS) of Curis, Inc. \u2013 MUN:CUS1", "summary": "This page provides financial data, specifically the basic earnings per share (basic EPS), for Curis, Inc. trading under the symbol CUS1 on the Munich Stock Exchange. The current market status is closed with no recorded trades.", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-income-statement/earnings-per-share-basic/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Revenue Breakdown \u2013 MUN:CUS1", "summary": "Curis, Inc. (MUN:CUS1) generated 8.04 million EUR in revenue last year, primarily from its \"Discovery and Development of Innovative Drug\" segment. This figure is down from 10.54 million EUR in the previous year. The United States was the company's largest regional contributor, ac", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-revenue/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Income Statement \u2013 MUN:CUS1", "summary": "This article provides financial statement details for Curis, Inc. (MUN:CUS1), specifically focusing on its income statement. It highlights that the total revenue for the last quarter was 0.00 EUR, a 100.00% decrease from the previous quarter, and the net income for Q1 2026 was -2", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-income-statement/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Financial Statements \u2013 MUN:CUS1", "summary": "This article provides financial statement insights for Curis, Inc. (MUN:CUS1), a biotechnology company focused on developing drug candidates for human cancers. It highlights key facts such as the company's founding in 2000 and its headquarters in Lexington, MA, along with its pip", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-overview/", "source_name": "TradingView", "published_at": "2026-07-07T18:40:14", "published_display": "07 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (STU:CUS1) Stock Price & 30 Year Financial Data", "summary": "This article provides 30-year financial data for Curis Inc (STU:CUS1), including detailed growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, and stock price performance. It presents key financial metrics such as market cap and enterprise value, along with various financ", "url": "https://www.gurufocus.com/stock/STU:CUS1/financials", "source_name": "GuruFocus", "published_at": "2026-07-07T11:13:36", "published_display": "07 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (STU:CUS1) Stock Earnings Transcripts", "summary": "This page provides a comprehensive list of Curis Inc (STU:CUS1) earnings call, extraordinary shareholders meeting, and conference call transcripts dating back to 2018. It includes financial data such as market cap, enterprise value, and various ratios, alongside stock performance", "url": "https://www.gurufocus.com/stock/STU:CUS1/transcripts", "source_name": "GuruFocus", "published_at": "2026-07-07T11:13:36", "published_display": "07 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia", "summary": "Curis announced that it has consented six patients in its Phase 2 trial of emavusertib for chronic lymphocytic leukemia (CLL). This development marks progress in evaluating the drug's potential for CLL treatment. Further details regarding the trial's progress and patient enrollme", "url": "https://www.moomoo.com/news/post/72528999/curis-consents-6-patients-in-phase-2-trial-of-emavusertib", "source_name": "Moomoo", "published_at": "2026-07-06T14:09:56", "published_display": "06 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Achieves Key Milestone in TakeAim CLL Study", "summary": "Curis has enrolled the first six patients in its TakeAim CLL study, with plans to dose five by July 2026, and expects to release initial clinical data in December 2026. The study aims to combine emavusertib with zanubrutinib to target chronic lymphocytic leukemia. Despite this pr", "url": "https://intellectia.ai/news/stock/curis-achieves-key-milestone-in-takeaim-cll-study", "source_name": "Intellectia AI", "published_at": "2026-07-06T14:09:56", "published_display": "06 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Consents First Six Patients in TakeAim CLL Study", "summary": "Curis, Inc. has enrolled the first six patients in its TakeAim CLL study, with eleven clinical sites already opened. The company expects to dose an initial five CLL patients by the end of July 2026 and release initial data in December 2026. This study combines emavusertib with a ", "url": "https://www.prnewswire.com/news-releases/curis-consents-first-six-patients-in-takeaim-cll-study-302818084.html", "source_name": "PR Newswire", "published_at": "2026-07-06T13:09:56", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis reaches first 6 patients in CLL study, July dosing on track", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOejJtdWdpZnJYbjcxNDBETVV2Z0xTZ2lMRkZMalZnS0pBdnlFcVUxdjN5Z1dWWmxWcE9qWV8yOGNyQ1Z4b2VTcWJobHZCcXFmZWR6NUpHZm9RRHNpaml1WF9RWTBCbzdzcnFqcURuU3hPeDU0X3Y2VlBCQ2dZekZqcHZuNV9USWdRQ3UtM2F4NnU0OTViWEdpOHV5MWI5ZFhnTTRZcVk4QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc outlines oncology pipeline as investors watch funding and trial progress", "summary": "Curis Inc, a clinical-stage biotech company, is advancing its targeted cancer pipeline, balancing funding needs with development timelines. The company focuses on precision medicines for oncology, developing small molecules to modulate key signaling pathways. Its financial stabil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/curis-inc-outlines-oncology-pipeline-as-investors-watch-funding-and-trial/69679860", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:40:55", "published_display": "03 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Curis (CRIS) Stock Soar After Hours?", "summary": "Curis, Inc. (CRIS) stock surged 8.51% after hours following the confirmation of a reverse stock split. The split, ranging from 1-for-5 to 1-for-25, is intended to help the company regain compliance with Nasdaq's minimum bid price rule. CRIS has a market capitalization of $16.52 m", "url": "https://www.sahmcapital.com/news/content/why-did-curis-cris-stock-soar-after-hours-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T00:39:32", "published_display": "03 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (NASDAQ: CRIS) sets 1-for-20 reverse split and adjusts equity awards", "summary": "Curis, Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective July 2, 2026, at 5:00 p.m. Eastern Time. This action consolidates 20 shares into one, with fractional shares rounded up, and will not alter the par value or authorized shares. Trading on a s", "url": "https://www.stocktitan.net/sec-filings/CRIS/8-k-curis-inc-reports-material-event-b9e9f220145d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:10:32", "published_display": "02 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) schedules reverse stock split and split-adjusted trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNXh0c2NEQm1qRlJpM3puZVdNOFZaTVBxd19seWRCVVNTSjRzc3B5aDZlNlRwNXp3OWFNQURXM3hGRlktdWdMMHo0Q2sxUTdqMDNGeFVaczZvRjBlbWpHYUtMR2EtdmY5OVJieTl6cERMc1RUTFg0eC1UYk9ZZFplT1RVeHJpTTVmNXZKWlQwWjZBcXI4OHJYU1czVTNWcmRySllaZy1jQ25zdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis opens 11 sites for emavusertib combo in TakeAim CLL trial", "summary": "", "url": "https://finance.yahoo.com/m/ace81d04-e831-3c78-9b45-4c3a7d9d0edb/curis-opens-11-sites-for.html", "source_name": "Clinical Trials Arena", "published_at": "2026-06-29T10:37:28+00:00", "published_display": "29 Jun 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxNY0tZTW93ckhFZE1iTFhKUnBIV0p4TWdpR2xtRG92YnJmSnUyOXJweFlKU1Y0V2dBQWhlTXJhZzIyRHhjYkZIWkQtaHBnMDFBVHlyalZkM3E3X2JXczRKOTdDM0JlNWdybXBRNkxNbzVZSmFnRHZKXzNMcnIxdmxmOUp4akJIWmgzNFBxVFRZRDg1Sm9vaWs2Vl9kUGNaZFFlR3d0T1JQNjc1NU1kTl85VFg5RW1mZTZocU9aNlpYMmdrbjExWGpxdDhoYmZoX0tiaDdJbVZWOFpXTGliNUpOZExKTUViMXg0N2EyZTBqT1c0ZUpjTjlsUnJPZTF6M04xNHN1c29wRnJscG1KSDg3TG95dE9YR19xMjdtU3pXVnUwZ0V2azBvRy1XczBXbmptWDl6QmV3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNendwZEhBaS00eHRBSlNINWZrVWlWVVRJU3VTdXhKeldkTG1OQS0yTDVYNno2VzNNZFNtM0poMVBCOHNPcVh2Zm1rUlE5cF9udkl4a2M1eGdzcnNUd2RUaGlsQm5zNHBaT0c4TkFjckpzUGk2X25DVGRuR3NpSnpreDNPSWNBX21xY1ZMTFVtVE9jd3FEZEZhSA?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/5f04ce22-9284-377c-8395-8c51f81f457f/curis-%28cris%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-06-02T17:20:24+00:00", "published_display": "02 Jun 2026 17:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curis, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/e1a8dd11-511c-367e-8d5f-c09036cc9772/curis%2C-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T12:30:00+00:00", "published_display": "13 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...", "summary": "", "url": "https://finance.yahoo.com/news/curis-inc-cris-q1-2026-050219392.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:02:19+00:00", "published_display": "13 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Provides First Quarter 2026 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWDlBdFJOUGJSUGQ5UHlOUXBhaHcwTUVGcEw3YllZY3RBMHNidFR2Mzhqd3dqRGdhTFI1VGNLM3dDRU5JOFRIOFE2bllkUmtWZ1hNT1RtbElocGR1OFY5elBfZEl0SUFXQ3lFZFc1MWZSTWZGM0dzaEhkQzRqWlhPRHBqSnFfVUgtNkNSaXJFRmNLYVN5R2E0U2VTZ1VtTnVtWmx3SnBHQmk?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUlByS19tVi1SRFNXNDlHaEVseXRMdDJadldVMGQ0M0tsZFhNNHVEQnJISTV6c0pSLWFZbFN2b0JuLTF2SmtqejJXQUVheW03ekthMHB0akE0NTVhRGtObXlBVGlLVU11VGFZSWNOR3ZmSFpjU3F1bFBudFFieDRVRFFmMmVQWjdJcE5WODQ2WmhNWVFQWGQtSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVEJDTGpSVkFvdXhMOTZTeUJXSzluNndhclNRa1lsNnlqdUkyY2c4a0pEVVQwTWViT2FiVGhnNlNxOEszcDl3VzJqRVE5el94TkdTMnRlanNrVFVEMmVHZER1TTI3UDFQZlBZemtCZXBjU2FLSWQwU2I1SE9RMUxHeEx2SmlIWWwxT0ZyeXJQZVJfcGdBTi1CS0taU0JTVHpTMHpHZXV0bnRWcERRX1ZCc2UtdG1lYlFaYVdUUXU0R0dJNGwxR0FjbFQweVNtajF6d1NVM0EzNFljZ0NqSHpJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Provides Third Quarter 2025 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOR0c4TU9LcC1yOTdaUHAxSWJUYXhBcm1VLVdxUnRYa29iWFFvZG5BWllxV014c1M0ZnpIanVPdmVWSzdDMENscHhETlNrUW9wLURuWnh1WGUyUmt0LWZicjYwUXd6UTNUOWtlblNFRDFGSDY2aDZqTWFSSlNnZ19DWktEanEtWWY5UXBaRjU2dGh3ZmtLaXgwbmpSUktPUXlBdWw3TDBYRTI?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Innovator Curis to Showcase Emavusertib IRAK4 Inhibitor at Major Healthcare Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN2hPWldFSGtDa2ZjTjIwY19BbTltRVlBY2haajgtYVltWFlDQm10M29mYVdrNGc3UFdMbDFKUzJTb2JyZXZwZlJ2UjBBTjJ4emUzUnRwRWlLNkFNdy1MRFhwVkdEcVVJSkkzQURVRjNMaWozeGF2TnJLN05HUDE3MEpvMTZiWnMyS0JaS3pVdDgtZmc4NENZUUF0Z2h5d015LTl0NGx0aW5ZUzJDN2c?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQV0hEY09GaUZOUEVPUmJzdEc2cFgtekVQZVZlTzVneTBKQndDYkpjSmVUQ0RqN2dqYldfRlR6NWRLVTk1b3lwLVpMeVI3YW80MUx0bnA0Szlab2sxNkVuc0w2NVJES1BGV3ZsVURDREJrN3g1VFRnQ3FtN0hfOFBMTXVtZG5FaG95RHZyWldfMVlBcFZNWkN1OXFQaFZTRWRDdG9YRmxYbXgtT1pVdTduQkVJLWpwZHNQUGNiYmJOT09TMVVDaVRTUFg1U3hUalE?oc=5", "source_name": "PR Newswire", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1kSnJObExYQmI4dU95Mk1rMzM3a3c2MmlVMDJ0Q0dqeW9meVhBdjlRbm5abXkydV9JbW1CUF9LWXNKbEFvWGd0eTA1SUV6Q0dvdDY4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:50:58+00:00", "published_display": "24 Apr 2025 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Curis stock jumps 11% on positive emavusertib trial data By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQb0dkTmJfWU03cUhlN0ZnWk9iVjl5RVB0TGtacTk1NzZzdE5NUnMwQ05WajgwRFRqNVByR1ZueXA4MERxbkFUQzNXWm9wREZlZ2xTSTF1UXo0UUZvTHFhcHFlcWFQRmtnTkFkZVN5a1N6TjVnVndSbkliaVI3NlQ3X0czdGNFY1o4ZDUwMGxVcUhSTkNwYnBibGhicm5sQ0ktRDdVQklYbTZjdjJBY2w4Zk5EZ2JUQk0?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-22T12:03:48+00:00", "published_display": "22 Jul 2026 12:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces Positive Emavusertib Update", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/curis-announces-positive-emavusertib-110000703.html", "source_name": "PR Newswire", "published_at": "2026-07-22T11:00:00+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis has consented 10 CLL patients; first five expected to dose by July's end", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNV0Jmbk5HLVlMTmM3TlNPZHVmVG1XSU1UX2JjWDNITTd0ZXd0RmZjY1hzaWxDNmNCNW80UGEyOG5vUnI5c29OU0xZZ1RmM3hGbmU2Y1pOYkltLWd4bFhuZVotMkZSUEdhWktqRHdxUlFWRDVYOURuYS1BT091Xy1qY3ZNeVVFc3Y3Z0NNLU0zbHp2WXU5Umc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T11:00:00+00:00", "published_display": "22 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity in earnings of Curis, Inc. \u2013 SWB:CUS1", "summary": "The article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its equity in earnings, with data sourced from ICE Data Services and FactSet. It indicates that the market for this stock is currently closed, with no trades reported.", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-07-16T05:40:18", "published_display": "16 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long term debt to total equity ratio of Curis, Inc. \u2013 SWB:CUS1", "summary": "This article focuses on the long-term debt to total equity ratio of Curis, Inc. (SWB:CUS1) as presented on TradingView. It appears to be a financial data page rather than a traditional article, providing a snapshot of this key financial metric for the biotechnology company. The c", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-statistics-and-ratios/long-term-debt-to-equity/", "source_name": "TradingView", "published_at": "2026-07-15T04:12:10", "published_display": "15 Jul 2026 04:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 SWB:CUS1", "summary": "This article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its price-to-book forward ratio. It's listed on the Stuttgart Stock Exchange under Health Technology/Biotechnology. The page displays general financial data, with market data provided", "url": "https://www.tradingview.com/symbols/SWB-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:16:58", "published_display": "14 Jul 2026 22:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (DB:CUS1) - Stock Analysis", "summary": "This article provides a detailed stock analysis of Curis (DB:CUS1), a biotechnology company specializing in cancer drug development. It covers the company's valuation, future growth prospects, past performance, financial health, and dividend policy, along with recent news and upd", "url": "https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-cus1/curis-shares", "source_name": "Simply Wall Street", "published_at": "2026-07-14T03:16:58", "published_display": "14 Jul 2026 03:16", "sentiment": "negative", "sentiment_pct": 20, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. (CUS1) Company Information", "summary": "This article provides company information for Curis, Inc. (CUS1), detailing its exchange listings, key information such as its ticker, industry, sector, and market capitalization, and sources of financial data. It also lists the number of employees, location, and the analysts who", "url": "https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-cus1/curis-shares/information", "source_name": "Simply Wall Street", "published_at": "2026-07-12T05:10:43", "published_display": "12 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net margin % of Curis, Inc. \u2013 DUS:CUS1", "summary": "This article provides the net margin percentage for Curis, Inc. (DUS:CUS1) on the TradingView platform. It shows the value and change over a period, indicating financial performance. The data is part of a larger financial overview for the company available on the platform.", "url": "https://www.tradingview.com/symbols/DUS-CUS1/financials-statistics-and-ratios/net-margin/", "source_name": "TradingView", "published_at": "2026-07-10T16:40:44", "published_display": "10 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) director John Hohneker receives 6,800 stock options at $5.29", "summary": "Curis Inc. director John Hohneker was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options, which relate to 6,800 shares of common stock, will vest entirely on July 7, 2027, and have an expiration date of July 6, 2036. This transactio", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-fcba261a8d1f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T01:40:44", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) CDO Jonathan Zung receives 48,285 stock options at $5.29 strike", "summary": "Jonathan B. Zung, Chief Development Officer of Curis Inc. (CRIS), was granted 48,285 employee stock options with an exercise price of $5.29 per share. These options are part of his compensation, designed to vest over time with 25% vesting on July 7, 2027, and subsequent quarterly", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-a90a83ce556c.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURIS (CRIS) CFO receives 48,285 stock options at $5.29 exercise price", "summary": "CURIS (CRIS) CFO Diantha Duvall was granted 48,285 employee stock options with an exercise price of $5.29 per share as part of her compensation. The options will vest over time, with 25% vesting on July 7, 2027, and subsequent quarterly vesting until July 7, 2030, and will expire", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-54909ecc2dc0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CURIS INC (CRIS) director granted 6,800 non-qualified stock options at $5.29", "summary": "CURIS INC director Anne Elizabeth Borgman was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This grant represents compensation-related equity rather t", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-2bd7149b0c57.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) director receives grant of 6,800 non-qualified stock options", "summary": "Curis Inc. director Kenneth I. Kaitin received a grant of 6,800 non-qualified stock options, exercisable at $5.29 per share. These options, which vest fully on July 7, 2027, and expire on July 6, 2036, are a compensation-related equity award rather than an open-market transaction", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-1b59c66ec14f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 HAM:CUS1", "summary": "This article provides financial information for Curis, Inc. (HAM:CUS1), specifically focusing on its \"Price to book forward\" metric. The content appears to be a financial data snippet from TradingView, indicating that the market for HAM:CUS1 is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/HAM-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Marc Rubin receives 6,800 Curis (CRIS) stock options at $5.29", "summary": "Curis Inc. director Marc Rubin was granted 6,800 non-qualified stock options at an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This transaction is considered a compensation-related award rather than", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-04073b6b912e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Curis Inc For: 9 July By Investing.com", "summary": "This article reports on a Form 4 filing for Curis Inc. (CRIS) dated July 9th. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by officers, directors, and 10% shareholders. The specific details of the Form 4 are not provided beyond the", "url": "https://ca.investing.com/news/stock-market-news/form-4-curis-inc-for-9-july-93CH-4728027", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (CRIS) director receives 6,800 stock options at $5.29", "summary": "Curis Inc. director Martyn D. Greenacre was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options expire on July 6, 2036, and will vest completely on July 7, 2027. This transaction, categorized as an \"A\" grant, links the director's com", "url": "https://www.stocktitan.net/sec-filings/CRIS/form-4-curis-inc-insider-trading-activity-4b8008a2eed2.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:14", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) CEO receives 110,090 employee stock options at $5.29", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTWNlcEtqWHJDSUo1dC1XLWJTSDNyaXVZM2Z6UTMzeV81MVMybGFra2hidUp1aDRuZ3hSNUxPT3lyR08wNkJwUG0tVjJDaTlwZFBOM054UWJBdlJsR2RDR1pYaFo4NGZKUFRZYThSek1VaUpYanJ6WXdTUTJwaHNXMTd0bEt4VjVHT0lsWFVvMmQwNzNvUTNhYXZWemlUYkNnSkd6VERB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Free cash flow per share of Curis, Inc. \u2013 LSX:A42DTL", "summary": "This article provides financial information for Curis, Inc. (LSX:A42DTL), specifically focusing on its free cash flow per share. It is presented on TradingView, a platform offering market data and financial tools.", "url": "https://www.tradingview.com/symbols/LSX-A42DTL/financials-statistics-and-ratios/free-cash-flow-per-share/", "source_name": "TradingView", "published_at": "2026-07-08T23:12:25", "published_display": "08 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 FWB:CUS1", "summary": "The article \"Price to book forward of Curis, Inc. \u2013 FWB:CUS1\" appears to be a stub or a placeholder page from TradingView, specifically concerning the financial metrics of Curis, Inc. (CUS1) on the Frankfurt Stock Exchange. It indicates that there is currently no trade data avail", "url": "https://www.tradingview.com/symbols/FWB-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T18:12:25", "published_display": "08 Jul 2026 18:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Curis, Inc. \u2013 MUN:CUS1", "summary": "This article provides financial information for Curis, Inc. (MUN:CUS1) on the Munich Stock Exchange, specifically focusing on its price-to-book forward ratio. It indicates that the market is closed with no recent trades. The content is primarily a data placeholder within a larger", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:40:14", "published_display": "08 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Basic earnings per share (basic EPS) of Curis, Inc. \u2013 MUN:CUS1", "summary": "This page provides financial data, specifically the basic earnings per share (basic EPS), for Curis, Inc. trading under the symbol CUS1 on the Munich Stock Exchange. The current market status is closed with no recorded trades.", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-income-statement/earnings-per-share-basic/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Revenue Breakdown \u2013 MUN:CUS1", "summary": "Curis, Inc. (MUN:CUS1) generated 8.04 million EUR in revenue last year, primarily from its \"Discovery and Development of Innovative Drug\" segment. This figure is down from 10.54 million EUR in the previous year. The United States was the company's largest regional contributor, ac", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-revenue/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Income Statement \u2013 MUN:CUS1", "summary": "This article provides financial statement details for Curis, Inc. (MUN:CUS1), specifically focusing on its income statement. It highlights that the total revenue for the last quarter was 0.00 EUR, a 100.00% decrease from the previous quarter, and the net income for Q1 2026 was -2", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-income-statement/", "source_name": "TradingView", "published_at": "2026-07-07T19:13:36", "published_display": "07 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Financial Statements \u2013 MUN:CUS1", "summary": "This article provides financial statement insights for Curis, Inc. (MUN:CUS1), a biotechnology company focused on developing drug candidates for human cancers. It highlights key facts such as the company's founding in 2000 and its headquarters in Lexington, MA, along with its pip", "url": "https://www.tradingview.com/symbols/MUN-CUS1/financials-overview/", "source_name": "TradingView", "published_at": "2026-07-07T18:40:14", "published_display": "07 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (STU:CUS1) Stock Price & 30 Year Financial Data", "summary": "This article provides 30-year financial data for Curis Inc (STU:CUS1), including detailed growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, and stock price performance. It presents key financial metrics such as market cap and enterprise value, along with various financ", "url": "https://www.gurufocus.com/stock/STU:CUS1/financials", "source_name": "GuruFocus", "published_at": "2026-07-07T11:13:36", "published_display": "07 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (STU:CUS1) Stock Earnings Transcripts", "summary": "This page provides a comprehensive list of Curis Inc (STU:CUS1) earnings call, extraordinary shareholders meeting, and conference call transcripts dating back to 2018. It includes financial data such as market cap, enterprise value, and various ratios, alongside stock performance", "url": "https://www.gurufocus.com/stock/STU:CUS1/transcripts", "source_name": "GuruFocus", "published_at": "2026-07-07T11:13:36", "published_display": "07 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia", "summary": "Curis announced that it has consented six patients in its Phase 2 trial of emavusertib for chronic lymphocytic leukemia (CLL). This development marks progress in evaluating the drug's potential for CLL treatment. Further details regarding the trial's progress and patient enrollme", "url": "https://www.moomoo.com/news/post/72528999/curis-consents-6-patients-in-phase-2-trial-of-emavusertib", "source_name": "Moomoo", "published_at": "2026-07-06T14:09:56", "published_display": "06 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Achieves Key Milestone in TakeAim CLL Study", "summary": "Curis has enrolled the first six patients in its TakeAim CLL study, with plans to dose five by July 2026, and expects to release initial clinical data in December 2026. The study aims to combine emavusertib with zanubrutinib to target chronic lymphocytic leukemia. Despite this pr", "url": "https://intellectia.ai/news/stock/curis-achieves-key-milestone-in-takeaim-cll-study", "source_name": "Intellectia AI", "published_at": "2026-07-06T14:09:56", "published_display": "06 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Consents First Six Patients in TakeAim CLL Study", "summary": "Curis, Inc. has enrolled the first six patients in its TakeAim CLL study, with eleven clinical sites already opened. The company expects to dose an initial five CLL patients by the end of July 2026 and release initial data in December 2026. This study combines emavusertib with a ", "url": "https://www.prnewswire.com/news-releases/curis-consents-first-six-patients-in-takeaim-cll-study-302818084.html", "source_name": "PR Newswire", "published_at": "2026-07-06T13:09:56", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis reaches first 6 patients in CLL study, July dosing on track", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOejJtdWdpZnJYbjcxNDBETVV2Z0xTZ2lMRkZMalZnS0pBdnlFcVUxdjN5Z1dWWmxWcE9qWV8yOGNyQ1Z4b2VTcWJobHZCcXFmZWR6NUpHZm9RRHNpaml1WF9RWTBCbzdzcnFqcURuU3hPeDU0X3Y2VlBCQ2dZekZqcHZuNV9USWdRQ3UtM2F4NnU0OTViWEdpOHV5MWI5ZFhnTTRZcVk4QQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc outlines oncology pipeline as investors watch funding and trial progress", "summary": "Curis Inc, a clinical-stage biotech company, is advancing its targeted cancer pipeline, balancing funding needs with development timelines. The company focuses on precision medicines for oncology, developing small molecules to modulate key signaling pathways. Its financial stabil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/curis-inc-outlines-oncology-pipeline-as-investors-watch-funding-and-trial/69679860", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T12:40:55", "published_display": "03 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Curis (CRIS) Stock Soar After Hours?", "summary": "Curis, Inc. (CRIS) stock surged 8.51% after hours following the confirmation of a reverse stock split. The split, ranging from 1-for-5 to 1-for-25, is intended to help the company regain compliance with Nasdaq's minimum bid price rule. CRIS has a market capitalization of $16.52 m", "url": "https://www.sahmcapital.com/news/content/why-did-curis-cris-stock-soar-after-hours-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T00:39:32", "published_display": "03 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (NASDAQ: CRIS) sets 1-for-20 reverse split and adjusts equity awards", "summary": "Curis, Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective July 2, 2026, at 5:00 p.m. Eastern Time. This action consolidates 20 shares into one, with fractional shares rounded up, and will not alter the par value or authorized shares. Trading on a s", "url": "https://www.stocktitan.net/sec-filings/CRIS/8-k-curis-inc-reports-material-event-b9e9f220145d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T13:10:32", "published_display": "02 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) schedules reverse stock split and split-adjusted trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNXh0c2NEQm1qRlJpM3puZVdNOFZaTVBxd19seWRCVVNTSjRzc3B5aDZlNlRwNXp3OWFNQURXM3hGRlktdWdMMHo0Q2sxUTdqMDNGeFVaczZvRjBlbWpHYUtMR2EtdmY5OVJieTl6cERMc1RUTFg0eC1UYk9ZZFplT1RVeHJpTTVmNXZKWlQwWjZBcXI4OHJYU1czVTNWcmRySllaZy1jQ25zdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis opens 11 sites for emavusertib combo in TakeAim CLL trial", "summary": "", "url": "https://finance.yahoo.com/m/ace81d04-e831-3c78-9b45-4c3a7d9d0edb/curis-opens-11-sites-for.html", "source_name": "Clinical Trials Arena", "published_at": "2026-06-29T10:37:28+00:00", "published_display": "29 Jun 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgJBVV95cUxNY0tZTW93ckhFZE1iTFhKUnBIV0p4TWdpR2xtRG92YnJmSnUyOXJweFlKU1Y0V2dBQWhlTXJhZzIyRHhjYkZIWkQtaHBnMDFBVHlyalZkM3E3X2JXczRKOTdDM0JlNWdybXBRNkxNbzVZSmFnRHZKXzNMcnIxdmxmOUp4akJIWmgzNFBxVFRZRDg1Sm9vaWs2Vl9kUGNaZFFlR3d0T1JQNjc1NU1kTl85VFg5RW1mZTZocU9aNlpYMmdrbjExWGpxdDhoYmZoX0tiaDdJbVZWOFpXTGliNUpOZExKTUViMXg0N2EyZTBqT1c0ZUpjTjlsUnJPZTF6M04xNHN1c29wRnJscG1KSDg3TG95dE9YR19xMjdtU3pXVnUwZ0V2azBvRy1XczBXbmptWDl6QmV3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNendwZEhBaS00eHRBSlNINWZrVWlWVVRJU3VTdXhKeldkTG1OQS0yTDVYNno2VzNNZFNtM0poMVBCOHNPcVh2Zm1rUlE5cF9udkl4a2M1eGdzcnNUd2RUaGlsQm5zNHBaT0c4TkFjckpzUGk2X25DVGRuR3NpSnpreDNPSWNBX21xY1ZMTFVtVE9jd3FEZEZhSA?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/5f04ce22-9284-377c-8395-8c51f81f457f/curis-%28cris%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-06-02T17:20:24+00:00", "published_display": "02 Jun 2026 17:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/e1a8dd11-511c-367e-8d5f-c09036cc9772/curis%2C-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-13T12:30:00+00:00", "published_display": "13 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...", "summary": "", "url": "https://finance.yahoo.com/news/curis-inc-cris-q1-2026-050219392.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:02:19+00:00", "published_display": "13 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Provides First Quarter 2026 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWDlBdFJOUGJSUGQ5UHlOUXBhaHcwTUVGcEw3YllZY3RBMHNidFR2Mzhqd3dqRGdhTFI1VGNLM3dDRU5JOFRIOFE2bllkUmtWZ1hNT1RtbElocGR1OFY5elBfZEl0SUFXQ3lFZFc1MWZSTWZGM0dzaEhkQzRqWlhPRHBqSnFfVUgtNkNSaXJFRmNLYVN5R2E0U2VTZ1VtTnVtWmx3SnBHQmk?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUlByS19tVi1SRFNXNDlHaEVseXRMdDJadldVMGQ0M0tsZFhNNHVEQnJISTV6c0pSLWFZbFN2b0JuLTF2SmtqejJXQUVheW03ekthMHB0akE0NTVhRGtObXlBVGlLVU11VGFZSWNOR3ZmSFpjU3F1bFBudFFieDRVRFFmMmVQWjdJcE5WODQ2WmhNWVFQWGQtSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVEJDTGpSVkFvdXhMOTZTeUJXSzluNndhclNRa1lsNnlqdUkyY2c4a0pEVVQwTWViT2FiVGhnNlNxOEszcDl3VzJqRVE5el94TkdTMnRlanNrVFVEMmVHZER1TTI3UDFQZlBZemtCZXBjU2FLSWQwU2I1SE9RMUxHeEx2SmlIWWwxT0ZyeXJQZVJfcGdBTi1CS0taU0JTVHpTMHpHZXV0bnRWcERRX1ZCc2UtdG1lYlFaYVdUUXU0R0dJNGwxR0FjbFQweVNtajF6d1NVM0EzNFljZ0NqSHpJ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Provides Third Quarter 2025 Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOR0c4TU9LcC1yOTdaUHAxSWJUYXhBcm1VLVdxUnRYa29iWFFvZG5BWllxV014c1M0ZnpIanVPdmVWSzdDMENscHhETlNrUW9wLURuWnh1WGUyUmt0LWZicjYwUXd6UTNUOWtlblNFRDFGSDY2aDZqTWFSSlNnZ19DWktEanEtWWY5UXBaRjU2dGh3ZmtLaXgwbmpSUktPUXlBdWw3TDBYRTI?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Innovator Curis to Showcase Emavusertib IRAK4 Inhibitor at Major Healthcare Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN2hPWldFSGtDa2ZjTjIwY19BbTltRVlBY2haajgtYVltWFlDQm10M29mYVdrNGc3UFdMbDFKUzJTb2JyZXZwZlJ2UjBBTjJ4emUzUnRwRWlLNkFNdy1MRFhwVkdEcVVJSkkzQURVRjNMaWozeGF2TnJLN05HUDE3MEpvMTZiWnMyS0JaS3pVdDgtZmc4NENZUUF0Z2h5d015LTl0NGx0aW5ZUzJDN2c?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQV0hEY09GaUZOUEVPUmJzdEc2cFgtekVQZVZlTzVneTBKQndDYkpjSmVUQ0RqN2dqYldfRlR6NWRLVTk1b3lwLVpMeVI3YW80MUx0bnA0Szlab2sxNkVuc0w2NVJES1BGV3ZsVURDREJrN3g1VFRnQ3FtN0hfOFBMTXVtZG5FaG95RHZyWldfMVlBcFZNWkN1OXFQaFZTRWRDdG9YRmxYbXgtT1pVdTduQkVJLWpwZHNQUGNiYmJOT09TMVVDaVRTUFg1U3hUalE?oc=5", "source_name": "PR Newswire", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Curis (CRIS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1kSnJObExYQmI4dU95Mk1rMzM3a3c2MmlVMDJ0Q0dqeW9meVhBdjlRbm5abXkydV9JbW1CUF9LWXNKbEFvWGd0eTA1SUV6Q0dvdDY4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:50:58+00:00", "published_display": "24 Apr 2025 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 63, "sentiment_summary": {"positive": 7, "negative": 6, "neutral": 50, "score": 50, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 10.86, "count": 22}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.63, "latest_week": "2026-07-17", "one_week_move": -6.7, "four_week_move": -45.0, "twelve_week_move": -61.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.072964, "market_dynamics_buy_signal": false, "relative_strength": -80.803559, "fair_value_gap": -95.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.1792, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, -45.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "TradingView", "count": 13}, {"label": "Market source", "count": 8}, {"label": "PR Newswire", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 22}, {"label": "Guidance", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.7% over one week, -45.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Curis stock jumps 11% on positive emavusertib trial data By Investing.com"}], "updated_at": "2026-07-22T12:45:09.947962+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}